Interferon therapy and lmmunlty'
Nearly fifty years have passed since viral interference was discovered by Hoskins (1935) working with two distinct strains of yellow fever virus. The first steps in the elucidation of heterologous interference were taken by Isaacs & Lindenmann (1957) , when they subjected chorioallantoic membranes to ultraviolet-treated influenza virus and showed that the buffer in which membranes were bathed contained antiviral activity. The extracellular product which had been liberated in response to exposure to virus was termed interferon. Even today, the ability of the interferon preparation to inhibit the production of a virus or prevent its cytotoxic activity is the basis for the interferon assay.
In the twenty-five years following their discovery, much of the work on interferons has concentrated on their mode of antiviral activity. This was reviewed by Professor D C Burke (University of Warwick) who defined interferons as proteins which exert nonspecific antiviral activities on many viruses, at least in homologous cells, through cellular metabolic processes involving the synthesis of both RNA and protein.
Interferon is not directly toxic to virus, but attaches itself to a non-infected cell and stimulates the cell to produce an intracellular environment which is hostile to virus growth. Initially the interferon binds to a receptor on the cell surface. This activates a genetic locus on chromosome 21 and induces in the cells new messenger RNA and proteins (Epstein et al. 1981) . The result is the formation of two enzymes, 2'5' oligoadenylate synthetase and a protein kinase, which when activated by the double-stranded RNA from the virus result in the inhibition of viral protein synthesis. The two biochemical pathways implicated both use adenosine triphosphate (ATP). In one system the ATP is converted into 2'5' A nucleotide, which in turn activates a nuclease that degrades messenger RNA and leads to an inhibition of protein synthesis. In the other system, the protein kinase activated by doublestranded RNA phosphorylates ATP with the small subunit of the protein synthesis initiation factor eIF-2, which inhibits viral protein synthesis (Freidman 1981) .
The range of stimuli which induce interferon production includes protozoa, endotoxin from bacteria, phytohaemagglutinin from plants, the double-stranded polymer polyriboinosinic acid: polyribocytidylic acid (poly I :C), as well as viruses. Many of the stimuli are species-specific. Originally interferon was divided into two types. Type I is now reclassified into alpha and beta forms. Human leukocytes in culture when stimulated with virus produce predominantly alpha-interferon.
Beta-interferon, immunologically distinct from the alpha variety, is formed by human fibroblast cultures when stimulated with virus or poly I :C. Human beta-interferon is species-specific and only induces antiviral activity in human cells, while alpha-interferon is active in human, bovine and porcine cefi cultures. There are at least 15 distinct genes. for human alphainterferon, and genes on chromosome 9 in man are activated both in alpha-and beta-interferon production (Burke 1980) . Type II interferon, now termed gamma-interferon, is quite separate from the alpha or beta variety. The antigenicity and cell receptors to which gamma-interferon attaches are quite distinct, as is the gene system which regulates its production. Alpha-and beta-interferons are stable at pH 2.0, while the antiviral activity of gamma-interferon is destroyed by this treatment. Gamma-interferon is produced by T-Iymphocytes in response to antigens, like tuberculin or mitogens, in the presence of macro phages (Epstein 1981) .
Interferon has more recently been shown to have varied effects on cells, inhibiting cell division, enhancing certain cell functions such as phagocytosis by macrophages, and altering the cell surface with enhanced expression of H-2 antigens. Little is known about the mechanisms involved (Gresser 1977) . Interferons also enhance the activity of natural killer cells (Saksela 1981) and affect both humoral and cellular components of the immune response. The primary or secondary antibody response can be enhanced whether 8 cells are exposed to antigen before or after sensitization. T-Iymphocyte function is variably affected by interferons. In vitro studies indicate that pretreatment with interferon inhibits cell proliferation in the mixed lymphocyte response, while in vivo in the mouse, both the cell proliferation and murine leukaemia virus activation reaction are inhibited by .interferon treatment in the graft-versus-host reaction. Allograft rejection is also delayed in mice receiving exogenous interferon (reviewed by Freidman 1981).
Dr G M Scott (Clinical Research Centre, Harrow) stated that clinical and experimental evidence suggested that while interferon probably helped in the recovery from viral infections, it may also cause direct toxic effects upon the host. Indications as to the biological importance of interferon in virus infections have come from varied observations. Early on, Isaacs & Hitchcock (1960) noted the temporal relationship between the production of interferon and the recovery from experimental influenza viral infection in man. Murphy and co-workers (1978) also found that the brisk febrile response to a wild H 3N 2 influenza virus coincided not only with the detection of virus but also with the presence of interferon in nasopharyngeal secretions. Virus shedding peaked at 48 hours and then rapidly disappeared soon after the peak of interferon secretion. However, the specific antibody response to the virus occurred later, suggesting that the resolution of the infection was due to interferon production rather than a specific antibody response.
Clinical observations have shown that severe and persistent virus infection are sometimes associated with decreased interferon production as well as specific deficiency in innate immune response. For example, immunosuppressed patients with lymphomas and other malignancies are known to have severe herpes zoster infections. It has been observed that the failure of the lesions to heal normally is associated with a deficiency in vesicle interferon production, despite active virus replication. To replace this interferon deficiency in herpes zoster infection, exogenous interferon has been given in controlled studies with remarkable results.
In a series of three studies with human leukocyte interferon involving 90 cancer patients with herpes zoster, the highest dose schedule tested caused limitation of local spread of zoster vesicles, less distal cutaneous spread and fewer local and visceral complications (Merigan et al. 1978) . In a more recent trial from Merigan's group, 44. children with cancer and varicelIa infection were also treated with human leukocyte interferon or placebo. Significantly, the mean number of days of new lesion formation was 3.8 in the interferon recipients as compared to 5.3 in those who received placebo (Arvin et al. 1982) .
An alternative to the use of interferon in acute infections has been to consider chronic infections in which there is no firm evidence for continuous or cyclical endogenous interferon production. In these studies, it must be possible to measure some effect objectively and then it becomes less important to use placebo controls in initial evaluation.
Chronic infections with cytomegalovirus, herpes simplex, rubella and hepatitis B viruses have been treated mainly on an uncontrolIed basis, with varying degrees of success (Scott & TyrreII 1980) . The most promising work is by Merigan and colIeagues (for review see Merigan 1981) who have given human leukocyte interferon either alone or with adenine arabinoside in chronic active hepatitis associated with hepatitis B virus (HBV). These HBV studies show that in perhaps one patient out often a permanent loss of the HBV-DNA polymerase, a measure of the whole virus in the peripheral blood, may be achieved by interferon alone. The best schedule of interferon alternating with adenine arabinoside (or its monophosphate derivatives) suggest a response in almost half the patients. Interestingly, interferon alone can always suppress virus replication as measured by HBV-DNA polymerase, but this does not often result in resolution of the disease.
Vaccinial and herpes simplex keratitis appear to improve with local instalIation of monkey kidney interferon (Jones et al. 1962) . Both leukocyte and fibroblast interferons given in several controlled trials have been shown to accelerate healing of acute herpes simplex dendritic ulcers (Sundmacher et al. 1978) .
Encouraging results in a controlIed trial using the Risdon gun have shown that repeated sprays of leukocyte interferon into the nasal cavity can inhibit experimental rhinovirus type 4 infection in volunteers (Merigan et al. 1973 ). More recently, in a double-blind placebo controlled study, a preparation of human leukocyte interferon purified by affinity chromatography using a monoclonal antibody NK2, applied in exactly the same way, reduced the incidence and severity of colds in volunteers challenged with rhinovirus 9 (Scott et al. 1982a) . A highly purified alpha-2-interferon, derived by recombinant DNA techniques from Escherichia coli. at the same dose also prevented rhinovirus 9 infections in susceptible volunteers (Scott et al. 1982b ). More recent experiments using self-administered nasal sprays have also been successful in preventing infection. There are, however, no published results yet from trials which attempted to treat a cold once it was established.
While interferons help to treat virus infections, it would appear that the headache, malaise, fever and chills that accompany influenza could be caused by the interferon induced by the virus. Volunteers injected with highly purified natural interferon, or even cloned leukocyte interferon, develop similar symptoms (Scott et al. 1981) .
In newborn mice, Gresser and his co-workers (1980) have reported toxic effects of interferon. Daily injection of mouse interferon causes liver necrosis and their death, while if the injections are stopped within eight days, the animals recover from the liver damage but eventually succumb to glomerulonephritis. In different experiments newborn mice were infected with lymphocytic choriomeningitis (LCM) virus, and when given antibody to interferon did not develop the liver necrosis associated with this infection. The glomerulonephritis characteristic of late LCM disease was also markedly inhibited. These experiments reinforce the suggestion that some of the changes associated with virus infection might be mediated by interferon. Dr Scott concluded by stating that although interferons have been shown to be effective in the treatment of a limited number of viral infections, it is still too early to predict how useful they would be in clinical practice.
Dr F Balkwill (Imperial Cancer Research Fund) discussed the potential of interferons as anticancer agents, where up until now exploitation of their potential has been hampered by the unavailability of these agents. However, advances in biotechnology and protein purification have now released enough interferon of varying types to conduct clinical trials. In designing such trials, all the available evidence must be considered concerning. the action of the interferons and also the biological differences between the different types and subtypes (Merigan 1981) . There are various in vitro properties of interferons which could be relevant to their anticancer activity. Interferons have growth inhibitory properties on a wide range of cells and are also capable of altering malignant cell lines to a more normal phenotype. They can also act indirectly on tumours by modifying host responses to the malignant cells, perhaps by enhancing natural killer cell activity or inhibiting stromal development (Taylor-Papadimitriou & Balkwilll982, Gresser & Tovey 1978) .
Experiments in vivo with transplantable mouse tumours and human tumours grown as xenografts in nude mice have shown that interferon therapy delays neoplastic progression in a dose-related fashion (Gresser & Tovey 1978 , Balkwill et al. 1980 , 1982 . Interferon is most effective with low tumour load. There is evidence for both a direct and indirect action of interferon (Gresser & Tovey 1978 , Balkwill et al. 1982 . The effect of interferons on experimental tumours compares favourably with that of single-agent chemotherapy, for interferon therapy halts tumour growth and formation of metastases. However, several experiments have shown that enhanced tumour regression can be seen when interferon therapy is combined with standard chemotherapy.
In the past some elegant clinical studies were performed but they were on small numbers of patients and generally anecdotal, some response having been seen in advanced breast cancer, lymphocytic lymphomas, multiple A case report from the urological literature reports failure of intravenous miconazole to control serious candidal infection in the newborn (Noe & Tonkin 1982) . I addressed the authors of that paper, as I do now, as to why amphotericin D, a proven antifungal drug, was not used (Wise 1982) . Intravenous miconazole has not been wel\ documented as a first-line defence against serious candidal infection. Recent literature supports amphotericin B as the more reliable antifungal agent (Medoff et al. 1982) .
Furthermore, the use of serological titres for antigen and antibodies has been extremely helpful in differentiating systemic from noninvasive candidal infection (Kozinn et al. 1982) .
